Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic lymphocytic leukemia (CLL); however, some patients experience adverse events (AEs) leading to discontinuation. Acalabrutinib is a potent, covalent BTK inhibitor with greater selectivity than ibrutinib. We evalu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Adv
Hauptverfasser: Awan, Farrukh T., Schuh, Anna, Brown, Jennifer R., Furman, Richard R., Pagel, John M., Hillmen, Peter, Stephens, Deborah M., Woyach, Jennifer, Bibikova, Elena, Charuworn, Prista, Frigault, Melanie M., Hamdy, Ahmed, Izumi, Raquel, Linghu, Bolan, Patel, Priti, Wang, Min Hui, Byrd, John C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2019
Schlagworte:
Clinical Trials and Observations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6517672/
https://ncbi.nlm.nih.gov/pubmed/31088809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018030007
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge